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The evidence favoring a role for prostaglandin E (PGE) as the neural mediator of the febrile
response is reviewed and considered under five different essential criteria which would need to be
satisfied, if such a role is to be accepted. These criteria are: (1) the ability of intracerebrally
microinjected exogenous PGE to cause fever; (2) the detection ofincreased levels ofendogenous
PGE in the brain during the normal production offever; (3) the ability ofsubstances that inhibit
the production and release of PGE to block normal fevers; (4) the ability of substances that are
specific PGE antagonists to inhibit normal fevers; and (S) the identification ofa specific site and
cell type for the releaseofPGE in response to theaction ofpyrogens. Evidence from theliterature
that supports these criteria is reviewed and presented in this format, and the conclusion is drawn
that the evidence available is more than sufficient to support the initial hypothesis.
Before reviewing the evidence favoring a role for PGE as the neural mediator in the
febrile response, I believe it is important to define specifically what is meant by the
febrile response. This is important, because I believe that much ofthe conflicting data
that have confused this issue in the recent literature stems from inappropriate
comparisons of different fever models. By this statement, I mean that the debate
should be confined to the role that PGE may or may not play in the normal
pathogenesis offever. The normal pathogenesis offever is defined as the progression of
steps that occur between the infection of the host by a foreign pathogen and the
manifestation of the febrile sign of hyperthermia [1,2]. A current, widely accepted
hypothesis ofthese events is illustrated in Fig. 1.
It is now generally acknowledged thatthe first step in thepathogenesis offeveris the
interaction of a variety of pathogens with bone marrow-derived mononuclear cells,
such as blood monocytes, and fixed tissuemacrophages, such as the Kupffer cells in the
liver [3]. That interaction results in the elaboration and release of an endogenous
pyrogen (EP) into the circulation. This monokine, whose major active component is
believed to be the polypeptide interleukin-1 (IL-1), reaches the brain via the cerebral
circulation, where it acts at or near the preoptic anterior hypothalamic (PO/AH)
neuropile to produce changes in the thermoregulatory pathways that result in fever.
Thus, for the purposes of this debate, I am defining the stimulus as circulating
endogenous pyrogen (produced experimentally by intravenous injection) and the
febrile response as the short-latency, monophasic increase in body temperature that
reaches its peak at 50-60 minutes after the injection of EP, and which gradually
declines thereafter. I believe that the use of the strict, almost oxymoronic, term of a
"normal pathogenesis" ofthe febrile response is important at the outset, because there
are other ways in which fever can be produced experimentally; these are artificial and
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FIG. 1. A current hypothesis on the pathogenesis
and mechanisms of the febrile event. A variety of
pathogens (activators) stimulate bone marrow-
derived cells to elaborate and release EP into the
circulation (1). This polypeptide travels via the
cerebral circulation to the blood-brain barrier,
where it is believed to somehow enter the PO/AH
neuropile (2). The EP is then thought to stimulate
the production of prostaglandin from an unknown
cell type. The prostaglandins are then thought to
alter the thermosensitivity of temperature-sensitive
neurons in the PO/AH area in such a manner as to
cause fever (3).
are unrelated to the normal progression of disease-initiated fevers. One such method
that is commonly employed is the intracerebroventricular (ICV) injection of EP. The
fever that results from using this technique is fundamentally different from that
produced by intravenously injected EP in a number of ways [4], as is illustrated in Fig.
2. It can be seen that thelatencyofonset forthefebrile response in therabbitafter ICV
injection ofEP is almost twice that which results from the intravenous injection (IV) of
EP. Furthermore, the rate ofrise ofbody temperature is much slower and the duration
of the febrile response is greatly extended when the intracerebral route of EP
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FIG. 2. A comparison of fevers produced by intravenous and intracerebroventricular
administration of EP into a group ofsix rabbits. Three distinct differences are apparent.
The latency to the onset of fever is much shorter (13 minutes) after IV injection than
after ICV injection (25 minutes). The rate of rise of T, (fever intensity) after IV
injection is greater (0.0220 C/minute) than in response to ICV injection (0.0140
C/minute). The time taken to reach peak rise in T. after IV injection (60 minutes) is
about halfthat taken after ICV injection (115 minutes).
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administration is used. These differences in the latency of fever onset and its duration
are commonly observed by other investigators and in other species of mammal [5,6].
Finally, there is absolutely no evidence that, in normal fevers, EP ever enters the
cerebral ventricles of the brain [7]. For these reasons, there seems no compelling
reason to believe that this type offever is produced by the same biochemical steps that
occur when fever is elicited intravenously. I believe that this distinction is an important
one, because I thinkthat much ofthe conflicting data appearing in the recent literature
that have confused the issue of the role of PGE in fever stems from inappropriate
comparisons made between these two different types offebrile responses [5].
In order to provide a framework around which to build the evidence for the role of
PGE as the neural mediator of the febrile response, I have proposed a set of criteria
that would need to be satisfied before such a proposition could be acceptable to an
objective observer. They are illustrated in Fig. 3.
I intend to concentrate primarily upon those criteria which are related to the
fever-producing actions of PGE and to the production of PGE within the brain in
response to the intravenous injection of EP. My colleague Dr. Bernheim will
concentrate on the biochemistry of the release of PGE in response to the EP stimulus
[8].
FEBRILE RESPONSES TO INTRACEREBRAL INJECTIONS
OF EXOGENOUS PGE
Clearly, there is little disagreement in the literature that intracerebral injection of
PGE produces fever [9,10]. While some might still hedge at the term "PGE fever,"
preferring to call it "PGE hyperthermia," I believe that theimportant criteria for fever
are met by PGE, and it can be regarded as a true pyrogen [11]. Nearly every
homeothermic species that has been injected with PGE intracerebrally exhibits a
febrile response, as well as several othervertebrate and invertebrate classes [9,10]. The
first report that implicated PGE in a fever-producing role was that of Sabine
Wendlandt and Tony Milton in 1970 [12]. They showed that when PGE was injected
into the lateral cerebral ventricle ofcats, it caused prompt and large increases in rectal
temperature. While they initially postulated a role for PGE in the normal regulation of
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FIG. 4. A compilation of the available PGE dose-response curves of three species of
mammals, the cat, the rabbit, and the rat, to both ICV and PO/AH microinjection ofat
least four different doses of PGE. The data are plotted semilogarithmically, and the
equations ofthesecurves have been determined by the method ofleast squares. Note the
similarity ofthe slopes in all six curves.
body temperature, it soon became obvious that a more likely role for PGE was that of
producing fever [13]. Shortly thereafter, Feldberg and Saxena [14] reported that
injections ofPGE directly into the tissue ofthe PO/AH region produced fever in cats,
and they also showed that injections into the tissue of the posterior region of the
hypothalamus were without effect on body temperature. These observations seemed to
replicate the earlier findings of Cooper et al. [15] and of Jackson [16], using
endogenous pyrogen, and reinforced the idea that the PO/AH was the site at which
pyrogens acted to produce fever. In 1973, our laboratory [11] reported the first direct
evidence that PGE acts as a pyrogen, rather than as a nonspecific hyperthermic agent,
and wealsoproduced a systematic feverdose-response curve for the intrahypothalamic
injection of PGE in rabbits. A recent survey of the literature has yielded only six
reports in which the febrile responses of one or more animals have been tested by at
least four different dose levels of PGE, either by the intracerebroventricular or the
intrahypothalamic route [11,14,17,18,19]. These reports also encompass three dif-
ferent species, the cat, the rabbit, and the rat, and for each species the febrile responses
to body ICV and PO/AH injections ofPGE were compared. These data are compiled
in Fig. 4. The first striking feature about these data is the similarity in the slopes ofall
six dose-response curves. While there is a tenfold difference in the dose-response
thresholds, thedose-response sensitivities vary by less than 8 percent. This fact is quite
remarkable considering the varied sources of the data, and it suggests that a similar
fever-producing mechanism is being activated in all three species of animals. More
puzzling, however, is the fact that there is little or no difference between the fever
dose-response curves obtained by ICV and by PO/AH injection of PGE in each
species. In both the cases ofthe rat and the rabbit, there are no significant differences
between either the thresholds or the slopes ofthedose-response curves produced by the
two different routes ofPGE administration. Ifthe site ofaction ofPGE were to reside
within the tissue of the PO/AH region, then one would expect that this route of
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injection should have a much higher sensitivity to PGE than the intracerebroventricu-
lar route, because the dilution occurring when PGE is injected into the cerebrospinal
fluid (CSF) ofthe lateral cerebral ventricle would reduce the final concentration ofthe
PGE by the time it diffused into the tissues of the PO/AH region. Such a dilution
would then be reflected in a difference between the two fever dose-response curves.
This is not the case, and it calls into doubt the premise that the site of action of PGE
resides within the PO/AH tissue. Furthermore, as long ago as 1973, we had made the
observation that double bilateral injections of PGE into the PO/AH region were no
more potent in producing fever in rabbits than single unilateral injection [11]. This,
too, seems incompatible with the idea that the specific site of action of PGE is the
PO/AH region. Thus, at this time I have serious reservations that the PO/AH is the
actual site of action of PGE in producing fever; this will be discussed later, when the
source of the release of PGE in response to endogenous pyrogen stimulation is
considered.
However, on the basis ofthe data that has been presented here, I submit that there is
clear support for the fulfillment of the first criterion for a mediator role for PGE in
fever.
RELEASE OF PGE DURING THE FEBRILE RESPONSE
The second criterion requires that PGE must be shown to be released when fever is
produced by normal pyrogenic stimuli. There have been several such demonstrations
over the past dozen years, both in response to endotoxin and endogenous pyrogens,
administered by both the intravenous and the intracerebroventricular routes
[20,21,22,23,24]. In every case the presence or absence of PGE in CSF was used as an
index ofPGE release in response to fever production.
The first studies of this nature were reported by Feldberg and Gupta [20] before
immunoassay techniques for prostaglandins were widely available, and the presence of
PGE in CSF, withdrawn from the cisterna magna ofthe cat, was demonstrated using a
rat stomach strip bioassay that was sensitive to PGE. Two important observations were
made using this technique. It was shown that the PGE-like activity in the CSF more
than doubled when animals were made febrile by an intravenous injection of shigella
endotoxin and, just as important, that this level of PGE-like activity in CSF was
decreased after antipyresis had been brought about by intravenous paracetamol
treatment.
While these data fulfilled, in some respects, the requirements ofthe second criterion,
they were however challenged on several grounds. It was pointed out that the bioassay
used was not specific for PGE and that the experiments in no way demonstrated any
causality between the presence of PGE in the CSF and the production of fever. Indeed,
Cranston et al. [22] reported a series ofexperiments in rabbits where they showed that
treatment with the weak antipyretic, sodium salicylate, could suppress the appearance
ofPGE activity in the CSF, while the animals still exhibited febrile responses. Some of
these objections were resolved by more specific immunoassay techniques for identify-
ing and quantifying PGE in a series of reports from several different laboratories such
as our own [23] and that of Dinarello and Coceani [24]. Furthermore, since the CSF
samples used in both Feldberg's and Cranston's studies were withdrawn from the
cisterna magna, a site distant from the hypothalamus, it is doubtful that Cranston's
ability to depress PGE levels in these CSF samples using weak antipyretics [22]
compromises the theory to any significant extent. In 1980, our laboratory reported a
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series ofexperiments in which the PGE content ofthird ventricular CSF was measured
under a variety of conditions that induced hyperthermia and thermogenesis in rabbits,
and it was shown that the only condition where PGE content rose significantly was
during fever produced by the intravenous injections ofendogenous pyrogen [23]. These
studies indicated that the increase in PGE concentrations in the CSF were not the
nonspecific result of hyperthermia per se, but were only associated with the febrile
response. Furthermore, the criticism that these experiments demonstrate no causality
in the relation between PGE and fever must also be rejected purely on logical grounds,
since the fulfillment of the first criterion (see the previous section) dictates that the
mere presence ofPGE in CSF must be regarded as a cause offever. At best, critics can
only protest that PGE may not be the sole cause of fever.
In summary, I would submit that the second criterion for the role of PGE as a
mediator in the febrile response has been completely fulfilled.
PREVENTION OF THE PRODUCTION AND RELEASE
OF PGE AND ANTIPYRESIS
It has long been known that aspirin-like drugs, along with a number of other drugs
such as the steroidal anti-inflammatories, have the capacity to inhibit the febrile
response. It was not until the detailed biochemistry of the prostinoid compounds was
investigated by Vane and his colleagues [13], however, that the relationship between
these antipyretic drugs and the enzymes that produce the prostaglandins became
apparent. The details of the biochemistry of prostanoids will not be reviewed here,
since they are discussed in Dr. Bernheim's presentation [8]. It should be noted,
however, that in at least two places in the prostaglandin production pathway two
different types of antipyretic compounds, aspirin-like drugs and the steroidal anti-
inflammatories, have been shown to inhibit the function of specific enzymatic steps
that are essential in the production of PGE [8]. Furthermore, we have recently
demonstrated that calcium channel antagonists such as verapamil and nifedipene have
the capacity to inhibit the febrile response of both rats and rabbits to endogenous
pyrogen [25]. We believe that this inhibition is related to the ability ofthese substances
to block one ofthe early steps in the PGE production pathway, since they do not inhibit
the action of exogenous PGE. Specifically, we believe that the calcium channel
antagonists act as antipyretics by blocking the EP receptor mechanism on the EP
"target cell" that is thought to release PGE in response to EP stimulation. Their most
likely mechanism ofaction is the prevention ofthe early rise in the intracellular level of
unbound calcium that is necessary for the activation of the enzyme phospholipase A2
[26]. The action of this enzyme is the first step in the production of arachidonic acid
from the phospholipids which are the precursors of all the prostinoid compounds. A
diagram, showing three probable sites of action of inhibitors of the production and
release of PGE, appears as Fig. 5.
In summary, there is overwhelming evidence that many substances which specifi-
cally inhibit the production of PGE also inhibit the normal febrile response, and
therefore the third criterion for the role of PGE as a mediator in the febrile response
appears adequately fulfilled.
THE ACTION OF PROSTAGLANDIN ANTAGONISTS
AND FEVER INHIBITION
Perhaps the most perplexing aspect of the debate about the role of PGE in the
pathogenesis of fever are the reports by Cranston et al. [5,27] and by Mitchell et al.
142PROSTAGLANDIN E IN FEVER
PHOSPHOLIPIDS
ARACHIDONIC ACID
11.1 ~~~yclooxygenasel
I
PROSTAGLANDINS
I CELL MEMBRANE
PGE ACTION ON PO/AH NEURONS
CAUSES FEBRILE RESPONSE
FIG. 5. A diagram illustrating the events
occurring when EP stimulates the putative tar-
get cell that is thought to release PGE and the
steps at which three different substances that
inhibit fever are believed to act to prevent the
productionofPGE. The EPmolecule attaches to
the cell EP receptor site, activating the calcium
channel, which causes unbound intracellular
[Ca"+] to rise inside the cell. Ca++ channel
antagonists such as verapamil and nifedipene
block this step, thereby preventing theactivation
ofthe enzyme phospholipase A2, which converts
phospholipids into arachidonic acid. The steroi-
dal anti-inflammatory drugs are also thought to
block the action of phospholipase A2 by impair-
ing calmodulin activity. Finally, aspirin-like
drugs are thought to block the activity of the
enzyme cyclooxygenase which converts arachi-
donic acid to prostaglandins.
[26] on the inability of PGE antagonists to block fever. These reports have claimed
that while the supposedly specific PGE antagonists SC 19220 and HR 546, adminis-
tered intracerebroventricularly, are effective in blocking the fever-producing effects of
PGE, they are unable to prevent the fevers produced by intracerebroventricular
injections of either endogenous pyrogen or the PGE precursor, sodium arachidonate.
This has been cited as evidence to repudiate the idea that PGE is a mediator of fever,
and, on the face ofit, the evidence can not be dismissed lightly. These results should be
viewed sceptically, however, because of the manner in which the EP fevers were
produced. As was stated earlier, at the outset of this paper, in any discussion of the
pathogenesis of fever production, it is important to distinguish the method by which
fever is being produced. During fever, EP normally reaches the brain via the cerebral
circulation. There is no reason to believe that EP enters the cerebrospinal fluid from
thecirculation, and indeed there is absolutely noevidence that EPever enters the brain
during theproduction offever [7]. Figure 6 shows acomparison ofthefebrileresponses
produced by PGE (ICV), EP (IV), and EP (ICV) taken from the work ofCranston et
al. [22,5].
It can be seen that the dynamics ofthe febrile response to intravenously injected EP
approximate more closely those ofan intracerebroventricular injection ofPGE, rather
than those of an intracerebroventricular injection of EP. I believe that this fact
demonstrates that the action of EP on the target cell that is thought to release PGE
must occur at a site that is diffusionally closer to the circulation than to the brain
neuropile. It is likely that those more slowly developing, longer-lasting fevers that
result from injection of EP into the cerebral ventricles are due to a direct, nonspecific
action ofEP on the neural tissue, rather than on the target cell that releases PGE [28].
Indeed, it may well be that this intracerebroventricular action ofEP is not mediated by
PGE. However, the mere fact that PGE antagonists, introduced into the cerebral
ventricles, do not block fevers produced by the intracerebroventricular injection ofEP,
cannot be used to repudiate the hypothesis that PGE is the mediator of the normal
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febrile response, since, under normal circumstances, EP reaches the brain via the
cerebral circulation rather than through the cerebral ventricles. For these reasons, I
would submit that the criterion regarding the action of prostaglandin antagonists on
fever production has neither been proved nor disproved, at least to my satisfaction,
although others may disagree.
THE SITE AND CELL TYPE RESPONSIBLE FOR THE
RELEASE OF PGE IN FEVER
Current thinking on the pathogenesis offever seems to favor the idea that EP, which
is carried to the brain in the cerebral circulation, crosses the blood-brain barrier to
enter the neuropile. There, it is believed to induce the production of PGE, which, in
turn, acts upon thermosensitive neurons in the PO/AH region to induce fever (see Fig.
1). Therefore, one would expect that the site and cell type responsible for the releaseof
PGE would be located within the neuropile ofthe PO/AH region ofthe brain. Indeed,
there are several studies reported in which minced whole brain tissue [28] or cultured
brain astrocytes [29] have been shown to respond to in vitro incubation with EP by
releasing PGE. Glial cells have also been suggested as possible sites of PGE release.
Caution is warranted when interpreting theseresults, however, sincethere is increasing
evidence that many cell types will release PGE in response to EP or IL-I incubation in
vitro. In truth, when one is attempting to identify the source ofPGE in response to EP
stimulation, there seems to be no paucity of cell types from which to choose
[2,8,28,29,30]. The real problem is identifying the correct source among many diverse
possibilities. Dr. Bernheim's paper reviews in some detail the PGE-releasing responses
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ofseveral different cell types to stimulation by EP and IL-1 [8]. However, it should be
noted that several mesenchymally derived cells possess this property in response to EP
and/or IL-I stimulation.
Furthermore, for the reasons stated earlier, I believe that the site ofaction of EP in
causing the release of PGE is closer to the circulation side of the blood-brain barrier
than it is to the brain neuropile. I base this opinion on the fact that fevers that result
from the intravenous injection of EP are faster in developing and shorter in duration
than those that result from either the intrahypothalamic or intracerebroventricular
injection ofEP [4]. As was pointed out earlier, there is no evidence to support the idea
that EPeven crosses the blood-brain barrier to reach the neuropile [7]. Clearly, the site
ofPGE release must be somewhere at or near the brain neuropile, but, given the facts
that the EP molecule is a large polypeptide of >15,000 daltons and that the cerebral
vasculature is predominantly composed of capillaries with tight-junctioned, non-
fenestrated endothelial cells [7], entry ofEP into the brain neuropile is doubtful.
I would prefer to approach the discussion of this problem in a slightly unorthodox
manner. Some time ago, we investigated the possibility that EP reached the blood-
brain interface via the peculiar vasculature of the circumventricular organs. These
organs are close to the brain parenchyma, outside the blood-brain barrier, and
accessible to larger protein molecules that cannot cross the blood-brain barrier. We
were particularly interested in the organum vasculosum lamina terminalis (OVLT),
which resides in the rostral wall ofthe third ventricle (lamina terminalis), adjacent to
the PO/AH region [31], and we obtained evidence that this region was, indeed,
involved in the mediation of the febrile response. In particular, we found that small
lesions placed in this region augmented and enhanced the sensitivity of both rats and
rabbits to intravenously injected EP [32]. Shortly thereafter, we also observed that the
fever sensitivity of rats to EP was also enhanced by the intravenous injection of
substances that possessed immuno-adjuvant properties and which stimulated the
phagocytic activity of cells of the reticuloendothelial system [33,34]. Naturally, we
then investigated whether there was any relationship between these two observations
on fever enhancement. We found that microinjection of very small amounts of
immuno-adjuvants directly into the OVLT region of rats was equally effective in
enhancing their responses to intravenously injected EP, as was the injection of much
larger quantities of the immuno-adjuvants intravenously [35]. Since the OVLT was
accessible to intravenously injected immuno-adjuvants and to EP, these observations
led us to postulate that the site of action of EP in the production of fever was located
within the OVLT itself and that the target cell for the action of EP was some kind of
immuno-adjuvant-sensitive reticuloendothelial cell, residing within the perivascular
space ofthe OVLT. Histological evidence for the presence ofa mesenchymally derived
phagocytic cell type within the perivascular space of the OVLT has been provided by
Murabe et al. [36]. We postulated that this cell was the source ofPGE that is released
in response to EP stimulation, and that the lipophilic PGE molecule then diffused
across the blood-brain barrier into the adjacent PO/AH neuropile and produced fever.
The increased sensitivity of animals to EP after immuno-adjuvant treatment could
then be explained by an increase in the sensitivity of the target cells' EP receptors
and/or the amount of PGE released by these cells in response to the EP stimulus
[35].
In reviewing the reported responses of animals to intracerebrally injected PGE, I
have noted some puzzling aspects that are not entirely consistent with our current
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FIG. 7. A comparison ofthe fever dose-response curves to PGE in rats when the PGE
is microinjected into either the PO/AH area or the OVLT region. Each curve is
composed from thedata derived from groups ofeight rats, and the slope and intercept of
the linear portion ofeach curve wasderived by regression analysis. Acomparison ofboth
the slope and the dose threshold ofthe two equations indicates that the OVLT region is
much more sensitive than the PO/AH area in the production offever by PGE.
concepts of the pathogenesis of fever. For example, if PGE were to act within the
PO/AH neuropile to produce fever, then one would expect that fevers produced in
response to intrahypothalamic injection ofPGE would be greater than those produced
in responsetointracerebroventricular injection ofPGE, yet, as was statedearlierand is
illustrated in Fig. 4, there is noevidence that PO/AH tissue is any moresensitive tothe
microinjection ofPGE than are the cerebral ventricles. This fact seems to indicate that
neither region is the site of action of PGE in the production of fever, but that both
regions are equally accessible to PGE. The location of the OVLT, adjacent to the
PO/AH region and protruding into thesupraoptic recess ofthethird ventricle, seemed
to fulfill this requirement [31]. Therefore, we compared the sensitivity of the OVLT
region and thePO/AH region tomicroinjection ofPGE in theproduction offever. The
results are shown in Fig. 7, where it can be seen that the slope of the dose-response
curvefor PGE in theOVLT is morethan twicethatobtained whenPGE isinjected into
the PO/AH region and the dose-response threshold for OVLT-induced fever has been
reduced by a factor offive.
We interpret these results as indicating that not only is the source of the release of
PGE located in the OVLT, but that the locus of the site of action of PGE also lies
within the confines ofthe OVLT.
In summary, considerable evidence now exists that EP or IL-I can cause the release
ofPGE from a variety ofmesenchymal cellswithin the body [8] and wehavepresented
evidence that a reticuloendothelial cell type, possibly located within the confines ofthe
OVLT, could be the source of PGE that mediates the febrile response to EP. Thus,
there are substantial grounds to believe that the fifth criterion for the role of PGE as
the mediator ofthe febrile response has been satisfied.
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A MODIFIED MODEL OF THE ROLE OF PGE IN THE
PATHOGENESIS OF FEVER
In completing this review ofthe evidence for a role for PGE as a mediator offever, I
would like to suggest some modifications to the schema, presented in Fig. 1 at the
outset of this review, that might account for the apparent discrepancies and disagree-
ments that have been mentioned in the course of this review. These modifications are
shown in Fig. 8, which depicts a coronal section through the rostral portion of the
PO/AH, showing theOVLT region that is situated medially within the rostral anterior
wall ofthe third ventricle ofbrain.
It also shows the fenestrated capillaries ofthe cerebral vasculature which supply the
parenchyma and perivascular spaces of the OVLT, and the PO/AH neuropile which
abuts the OVLT region bilaterally. It is known that the perivascular spaces of the
OVLT contain phagocytic reticuloendothelial-like cells that are capable oftaking up a
variety of large molecular weight substances such as horseradish peroxidase and
trypan blue-bound albumen which are excluded by the blood-brain barrier [36]. We
hypothesize that these mesenchymal cells are the target cells for circulating EP. When
EP arrives at the brain via the cerebral circulation, it is excluded from the neuropile
proper due to its large molecular size (>15,000 daltons) and because of the typical
non-fenestrated, tight-junctioned endothelial cells that invest all cerebral capillaries.
However, the OVLT is an exception to this rule, in that its capillaries are fenestrated,
which allow large molecules into its perivascular spaces [31]. Here, the EP is
postulated to stimulate the phagocytic mesenchymal cell, which like all macrophages
has the capacity to release PGE, if appropriately stimulated [29]. We postulate that
these cells possess specific receptors for EP. Once PGE is released from these cells in
response to the EPstimulus, twopossibilities exist. The first is that the PGE crosses the
tight-junctioned ependymal cells that form the blood-brain barrier and separate the
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OVLT region from the PO/AH neuropile proper [37]. PGE, due to its small molecular
size and its lipophilic character, has no difficulty in crossing the blood-brain barrier,
and it has been shown to be extremely pyrogenic when it is deposited within the
PO/AH region [ 1]. It is then presumed that fever production is due to a direct action
of the PGE on the PO/AH neurons controlling temperature regulation (Fig. 7,
left-hand side). The second possibility is that of a direct action of PGE on neural
elements known to reside within the OVLT [38,39]. This must be considered because
of the fact that in the rat we have shown that any given dose of PGE, microinjected
directly into the OVLT region, is more effective in producing fever than when it is
injected into the PO/AH area (see Fig. 7). This possibility is depicted by the
configuration ofneurons that are illustrated on the right-hand side ofthe model in Fig.
8.
In summary, the evidence favoring a role for PGE as the neural mediator of fever
has been reviewed under five essential criteria that must be satisfied in order to support
such a hypothesis. Exogenous PGE, delivered intracerebrally, has been shown to cause
fevers in all mammalian species studied thus far. Fever production caused by the
natural pyrogenic stimulus, EP, has been shown to be accompanied by the release of
endogenous PGE into the CSF. A variety of substances that are known to block the
production of PGE all exhibit antipyretic activity. An anatomical site and cell type,
close to the brain and the cerebral circulation, has been identified as a possible source
of release and the possible site of action of PGE in response to stimulation by
circulating EP. The only criterion for which the evidence is still equivocal is whether
PGE antagonists can block normal fever production. Therefore, on the balance of
evidence presented, it is submitted that a strong case exists for believing that PGE is,
indeed, the neural mediator offever.
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